169 related articles for article (PubMed ID: 35166953)
1. Letter to the Editor: Comment on ''Cytoreductive Surgery with or without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer: A Phase 3 Clinical Trial''.
Carneiro VCG; Ramalho NM
Ann Surg Oncol; 2022 May; 29(5):3351-3352. PubMed ID: 35166953
[No Abstract] [Full Text] [Related]
2. Combining HIPEC to Interval Surgery in Ovarian Cancer? One Step Forward with a Second Randomized Study: Comment on "Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer-A Phase 3 Clinical Trial".
Noiret B; Bakrin N; Eveno C
Ann Surg Oncol; 2022 May; 29(5):3357-3358. PubMed ID: 35192155
[No Abstract] [Full Text] [Related]
3. Post-Publication Discussion Regarding Cytoreductive Surgery with or Without HIPEC After Neoadjuvant Chemotherapy in Ovarian Cancer.
Cascales Campos PA; González Gil A
Ann Surg Oncol; 2022 May; 29(5):3361-3362. PubMed ID: 35254577
[No Abstract] [Full Text] [Related]
4. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
Gelissen JH; Adjei NN; McNamara B; Mutlu L; Harold JA; Clark M; Altwerger G; Dottino PR; Huang GS; Santin AD; Azodi M; Ratner E; Schwartz PE; Andikyan V
Ann Surg Oncol; 2023 Sep; 30(9):5597-5609. PubMed ID: 37358686
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
6. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
7. A novel treatment protocol with 6 cycles of neoadjuvant chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in stage III primary ovarian cancer.
Marrelli D; Petrioli R; Cassetti D; D'Ignazio A; Marsili S; Mazzei MA; Lazzi S; Roviello F
Surg Oncol; 2021 Jun; 37():101523. PubMed ID: 33545658
[TBL] [Abstract][Full Text] [Related]
8. Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) (OVHIPEC-2).
Gregory SN; Ryan CE; Hernandez JM; Sonke GS; Aronson SL; Zivanovic O; van Driel WJ;
Ann Surg Oncol; 2023 Apr; 30(4):1950-1952. PubMed ID: 36581719
[No Abstract] [Full Text] [Related]
9. Developing a hyperthermic intraperitoneal chemotherapy (HIPEC) gynecologic oncology program: a Canadian experience.
Neveu J; Tremblay E; Mercier F; Garneau S; Cormier B
Int J Gynecol Cancer; 2023 Dec; 33(12):1957-1965. PubMed ID: 38011988
[TBL] [Abstract][Full Text] [Related]
10. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
11. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer.
Mutlu Sütcüoğlu B; Sütcüoğlu O
Lancet Oncol; 2023 Dec; 24(12):e457. PubMed ID: 38039999
[No Abstract] [Full Text] [Related]
12. Mininvasive Cytoreduction Surgery plus HIPEC for Epithelial Ovarian Cancer: A Systematic Review.
Ronsini C; Pasanisi F; Greco P; Cobellis L; De Franciscis P; Cianci S
Medicina (Kaunas); 2023 Feb; 59(3):. PubMed ID: 36984422
[No Abstract] [Full Text] [Related]
13. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer - Authors' reply.
Aronson SL; Sonke GS; van Driel WJ
Lancet Oncol; 2023 Dec; 24(12):e458. PubMed ID: 38040000
[No Abstract] [Full Text] [Related]
14. Quality of life outcomes from the randomized trial of hyperthermic intraperitoneal chemotherapy following cytoreductive surgery for primary ovarian cancer (KOV-HIPEC-01).
Kim JH; Lee DE; Lee Y; Ha HI; Chang YJ; Chang SJ; Park SY; Lim MC
J Gynecol Oncol; 2022 Jul; 33(4):e54. PubMed ID: 35712968
[TBL] [Abstract][Full Text] [Related]
15. Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer?
Praiss AM; Moukarzel LA; Zivanovic O
Curr Opin Obstet Gynecol; 2023 Feb; 35(1):21-26. PubMed ID: 36595646
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 trial of short-course Hyperthermic IntraPeritoneal Chemotherapy (HIPEC) at interval cytoreductive surgery (iCRS) for advanced ovarian cancer.
Batista TP; Carneiro VCG; Tancredi R; Badiglian Filho L; Rangel RLC; Lopes A; Sarmento BJQ; Leão CS
Rev Col Bras Cir; 2022; 49():e20223135. PubMed ID: 35239855
[TBL] [Abstract][Full Text] [Related]
17. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
18. Hyperthermic intraperitoneal chemotherapy (HIPEC) for gynecological cancer.
Tsuyoshi H; Inoue D; Kurokawa T; Yoshida Y
J Obstet Gynaecol Res; 2020 Sep; 46(9):1661-1671. PubMed ID: 32715605
[TBL] [Abstract][Full Text] [Related]
19. Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
Wethington SL; Armstrong DK; Johnston FM
JAMA Surg; 2022 May; 157(5):383. PubMed ID: 35262650
[No Abstract] [Full Text] [Related]
20. Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer.
Mikkelsen MS; Christiansen T; Petersen LK; Blaakaer J; Iversen LH
J Surg Oncol; 2019 Sep; 120(3):550-557. PubMed ID: 31267569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
